상세 보기
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With <i>NTRK</i> Fusion-Positive Solid Tumors
- Demetri, George D.;
- De Braud, Filippo;
- Drilon, Alexander;
- Siena, Salvatore;
- Patel, Manish R.;
- ... Lee, Jeeyun;
- 외 17명
WEB OF SCIENCE
205SCOPUS
236초록
Purpose: Entrectinib potently inhibits tropomyosin receptor kinases (TRKAs)/B/C and ROS1, and previously induced deep [objective response rate (ORR) 57.4%] and durable [median duration of response (DoR) 10.4 months] responses in adults with NTRK fusion-positive solid tumors from three phase I/II trials. This article expands prior reports with additional patients and longer follow-up. Patients and Methods: Patients with locally advanced/metastatic NTRK fusion-positive solid tumors and >= 12 months' follow-up were included. Primary endpoints were ORR and DoR by blinded independent central review (BICR); secondary endpoints included progression-free survival (PFS), intracranial efficacy, and safety. The safety-evaluable populations included all patients who had received >= 1 entrectinib dose. Results: At clinical cut-off (August 31, 2020), the efficacy-evaluable population comprised 121 adults with 14 tumor types and >= 30 histologies. Median follow-up was 25.8 months; 61.2% of patients had a complete (n = 19) or partial response (n = 55). Median DoR was 20.0 months [95% confidence interval (CI), 13.0-38.2]; median PFS was 13.8 months (95% CI, 10.1-19.9). In 11 patients with BICR-assessed measurable central nervous system (CNS) disease, intracranial ORR was 63.6% (95% CI, 30.8-89.1) and median intracranial DoR was 22.1 (95% CI, 7.4-not estimable) months. The safety profile of entrectinib in adults and pediatric patients was aligned with previous reports. Most treatment-related adverse events (TRAEs) were grade 1/2 and manageable/reversible with dose modifications. TRAE-related discontinuations occurred in 8.3% of patients. Conclusions: With additional clinical experience, entrectinib continues to demonstrate durable systemic and intracranial responses and can address the unmet need of a CNS-active treatment in patients with NTRK fusion-positive solid tumors.
키워드
- 제목
- Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With <i>NTRK</i> Fusion-Positive Solid Tumors
- 저자
- Demetri, George D.; De Braud, Filippo; Drilon, Alexander; Siena, Salvatore; Patel, Manish R.; Cho, Byoung Chul; Liu, Stephen, V; Ahn, Myung-Ju; Chiu, Chao-Hua; Lin, Jessica J.; Goto, Koichi; Lee, Jeeyun; Bazhenova, Lyudmila; John, Thomas; Fakih, Marwan; Chawla, Sant P.; Dziadziuszko, Rafal; Seto, Takashi; Heinzmann, Sebastian; Pitcher, Bethany; Chen, David; Wilson, Timothy R.; Rolfo, Christian
- 발행일
- 2022-04-01
- 유형
- Article
- 권
- 28
- 호
- 7
- 페이지
- 1302 ~ 1312
- 언어
- ENG
- 출판사
- American Association for Cancer Research
- 발행국가
- 미국
- 분량
- 11 페이지
- ISSN
- E 1557-3265
P 1078-0432